316 related articles for article (PubMed ID: 19215609)
21. Pegylated liposomal doxorubicin in recurrent malignant glioma: analysis of a case series.
Glas M; Koch H; Hirschmann B; Jauch T; Steinbrecher A; Herrlinger U; Bogdahn U; Hau P
Oncology; 2007; 72(5-6):302-7. PubMed ID: 18198491
[TBL] [Abstract][Full Text] [Related]
22. Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction.
Li Y; Finkel KW; Hu W; Fu S; Liu J; Coleman R; Kavanagh JJ
Gynecol Oncol; 2007 Aug; 106(2):375-80. PubMed ID: 17512575
[TBL] [Abstract][Full Text] [Related]
23. Applying the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome in primary cutaneous marginal zone lymphoma.
Gerami P; Wickless SC; Rosen S; Kuzel TM; Ciurea A; Havey J; Guitart J
J Am Acad Dermatol; 2008 Aug; 59(2):245-54. PubMed ID: 18486274
[TBL] [Abstract][Full Text] [Related]
24. Pegylated doxorubicin for primary cutaneous T cell lymphoma: a report on ten patients with follow-up.
Wollina U; Graefe T; Kaatz M
Ann N Y Acad Sci; 2001 Sep; 941():214-6. PubMed ID: 11594577
[No Abstract] [Full Text] [Related]
25. Phase I trial of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy in patients undergoing cytoreduction for advanced intra-abdominal malignancy.
Harrison LE; Bryan M; Pliner L; Saunders T
Ann Surg Oncol; 2008 May; 15(5):1407-13. PubMed ID: 18157576
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA).
Ribrag V; Gisselbrecht C; Haioun C; Salles G; Golfier JB; Ertault M; Ferme C; Briere J; Brice P; Mounier N
Cancer; 2009 Oct; 115(19):4540-6. PubMed ID: 19593797
[TBL] [Abstract][Full Text] [Related]
27. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
Trudeau ME; Clemons MJ; Provencher L; Panasci L; Yelle L; Rayson D; Latreille J; Vandenberg T; Goel R; Zibdawi L; Rahim Y; Pouliot JF
J Clin Oncol; 2009 Dec; 27(35):5906-10. PubMed ID: 19858391
[TBL] [Abstract][Full Text] [Related]
28. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
Tanyi JL; Smith JA; Ramos L; Parker CL; Munsell MF; Wolf JK
Gynecol Oncol; 2009 Aug; 114(2):219-24. PubMed ID: 19446868
[TBL] [Abstract][Full Text] [Related]
29. Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas.
Neelis KJ; Schimmel EC; Vermeer MH; Senff NJ; Willemze R; Noordijk EM
Int J Radiat Oncol Biol Phys; 2009 May; 74(1):154-8. PubMed ID: 18834672
[TBL] [Abstract][Full Text] [Related]
30. Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody.
Lacouture ME; Baron JM; Jani AB; Laumann AE; Soltani K
Clin Exp Dermatol; 2005 Jan; 30(1):46-8. PubMed ID: 15663503
[TBL] [Abstract][Full Text] [Related]
31. Primary cutaneous large B-cell lymphomas of the legs. A distinct type of cutaneous B-cell lymphoma with an intermediate prognosis. Dutch Cutaneous Lymphoma Working Group.
Vermeer MH; Geelen FA; van Haselen CW; van Voorst Vader PC; Geerts ML; van Vloten WA; Willemze R
Arch Dermatol; 1996 Nov; 132(11):1304-8. PubMed ID: 8915307
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
Rose PG; Blessing JA; Lele S; Abulafia O
Gynecol Oncol; 2006 Aug; 102(2):210-3. PubMed ID: 16478630
[TBL] [Abstract][Full Text] [Related]
33. Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer.
Mlineritsch B; Schabel-Moser R; Andel J; Fridrik M; Moik M; Mayer P; Russ G; Rass C; Greil R;
Onkologie; 2009 Feb; 32(1-2):18-24. PubMed ID: 19209014
[TBL] [Abstract][Full Text] [Related]
34. Skin problems associated with pegylated liposomal doxorubicin-more than palmoplantar erythrodysesthesia syndrome.
Mangana J; Zipser MC; Conrad C; Oberholzer PA; Cozzio A; Knuth A; French LE; Dummer R
Eur J Dermatol; 2008; 18(5):566-70. PubMed ID: 18693162
[TBL] [Abstract][Full Text] [Related]
35. Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas.
Pulini S; Rupoli S; Goteri G; Pimpinelli N; Alterini R; Tassetti A; Scortechini AR; Offidani M; Mulattieri S; Stronati A; Brandozzi G; Giacchetti A; Mozzicafreddo G; Ricotti G; Filosa G; Bettacchi A; Simonacci M; Novelli N; Leoni P
Haematologica; 2007 May; 92(5):686-9. PubMed ID: 17488695
[TBL] [Abstract][Full Text] [Related]
36. Pegylated liposomal doxorubicin and carboplatin in late-relapsing ovarian cancer: a GINECO group phase II trial.
Weber B; Lortholary A; Mayer F; Bourgeois H; Orfeuvre H; Combe M; Platini C; Cretin J; Fric D; Paraiso D; Pujade-Lauraine E
Anticancer Res; 2009 Oct; 29(10):4195-200. PubMed ID: 19846972
[TBL] [Abstract][Full Text] [Related]
37. Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin.
Gordinier ME; Dizon DS; Fleming EL; Weitzen S; Schwartz J; Parker LP; Granai CO
Gynecol Oncol; 2006 Oct; 103(1):72-4. PubMed ID: 16494932
[TBL] [Abstract][Full Text] [Related]
38. The applicability and prognostic value of the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: results on a large cohort of primary cutaneous B-cell lymphomas and comparison with the system used by the Dutch Cutaneous Lymphoma Group.
Senff NJ; Willemze R
Br J Dermatol; 2007 Dec; 157(6):1205-11. PubMed ID: 17941944
[TBL] [Abstract][Full Text] [Related]
39. Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma.
Jakubowiak AJ; Kendall T; Al-Zoubi A; Khaled Y; Mineishi S; Ahmed A; Campagnaro E; Brozo C; Braun T; Talpaz M; Kaminski MS
J Clin Oncol; 2009 Oct; 27(30):5015-22. PubMed ID: 19738129
[TBL] [Abstract][Full Text] [Related]
40. Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases.
Grange F; Beylot-Barry M; Courville P; Maubec E; Bagot M; Vergier B; Souteyrand P; Machet L; Dalac S; Esteve E; Templier I; Delaporte E; Avril MF; Robert C; Dalle S; Laroche L; Delaunay M; Joly P; Wechsler J; Petrella T
Arch Dermatol; 2007 Sep; 143(9):1144-50. PubMed ID: 17875875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
